Home > News & Opinion > Viewpoint

Viewpoint

  • Optimizing behavioral assays for mouse models of autism
    23 September 2014
    Comments ( 3 )

    As the number of autism rodent models climbs, it is a good time for the field to step back and consider the best practices for assessing autism-like symptoms in rodents, says Jacqueline Crawley.

  • Why inferring autism's causes from epidemiology is dangerous
    29 July 2014
    Comments ( 8 )

    Epidemiological 'just-so' stories, which infer causes of autism from general trends in prevalence, are in danger of repeating the mistakes of social Darwinism, says Mayada Elsabbagh.

  • The urgent need to shorten autism's diagnostic odyssey
    15 July 2014
    Comments ( 8 )

    With the rate of autism now at 1 in 68 people and climbing, the need for solutions that reach the risk population more quickly and effectively has never been more real, say Dennis Wall and Glenn Saxe.

  • How to evaluate new medications for autism
    10 June 2014
    Comments ( 7 )

    There are no available medications for treating autism’s core symptoms, but there are several candidates in clinical trials. Jeremy Veenstra-VanderWeele describes the factors researchers must take into account when developing drugs for the disorder.

  • Signaling pathways link autism, schizophrenia
    27 May 2014
    Comments ( 3 )

    Autism, schizophrenia and intellectual disability share underlying deficits in pathways that regulate how the brain encodes new experiences, says Jason Shepherd.

1 2 3 4 15 Next >